ProteoNic, a leading provider of technology and services for efficient production of biologics, announced it has licensed its premium 2G UNic\u2122 technology for boosting therapeutic protein production to Gilead Sciences, Inc. (Nasdaq: GILD). \u00a0Under the agreement, Gilead gains non-exclusive commercial rights for application of ProteoNic\u2019s technology platform to the development of its proprietary products from mammalian cells. Financial details of the agreement were not disclosed.<\/p>\n\n\n\n
ProteoNic\u2019s protein expression technology improves production levels across a range of mammalian host cells and selection systems. It is applicable to all relevant protein classes, including standard antibodies, bispecifics, recombinant polyclonals and complex multi-chain molecules, and enables the economically viable production of difficult to express proteins. By increasing transcription and translation rates via a combination of novel genetic elements, the highest possible production levels are achieved without impacting product quality and cell line stability. 2G UNic\u2122 technology can be readily combined with other protein expression-enhancing technologies to improve their performance and is functional in random and targeted integration.<\/p>\n\n\n\n